Abstract Skin colonisation is an important source for central venous catheter (CVC) colonisation and infection. This study intended to identify risk factors for skin colonisation prior to CVC placement (baseline colonisation) and within 10 days after CVC insertion (subsequent colonisation), for CVC-tip colonisation and for bloodstream infection (BSI). Within a randomised clinical trial, data of 219 patients with haematological malignancies and inserted CVC (with a total of 5,501 CVC-days and 4,275 days at risk) in two university hospitals were analysed. Quantitative skin cultures were obtained from the insertion site before CVC placement and at regular intervals afterwards. CVC-tip cultures were taken on CVC removal and data collection was performed. Statistical analysis included linear and logistic regression models. Age was an independent risk factor for colonisation prior to CVC placement (baseline colonisation). Independent risk factors for subsequent colonisation were baseline colonisation and male gender. High level of subsequent skin colonisation at the insertion site was a predictor of CVC-tip colonisation, and a predictor of BSI. High level of skin colonisation predicts catheter tip colonisation and possibly subsequent infection. Sustained reduction of bacterial growth at the CVC insertion site is therefore indispensable. Male patients are at particular risk for skin colonisation and may be a target population for additional insertion-site care before and during catheterisation.
Introduction
Central venous catheters (CVC) are indispensable in medical care of patients receiving chemotherapy or intensive care. However, CVC use is associated with a significant risk of infectious complications [1] [2] [3] . CVCassociated bloodstream infection (CA-BSI) poses a serious threat to affected patients as the attributable mortality may exceed 25% [4, 5] . Furthermore, BSIs are a considerable financial burden for healthcare providers [4, [6] [7] [8] [9] . Neutropenic patients are at especially high risk for BSI with rates up to 14/1,000 catheter days [10] .
Most important source of microorganisms in shortterm CVC-associated BSI is the skin at the insertion site [11] . Generally, catheter colonisation follows the extraluminal route in short-term CVC whereas the intraluminal route (e.g., via the catheter-hub) is considered common in long-term CVC [11] .
High level of skin colonisation at the insertion site was shown to be a predictor for catheter-associated BSI and, conversely, lowering the microbial burden at the insertion site reduced catheter-associated BSI rates [2] . Thus, identifying risk factors associated with skin and cathetertip colonisation can provide a framework for prevention before colonisation progresses to CA-BSI. Therefore, the objective of this study was to identify risk factors for skin colonisation at the insertion site (using quantitative skin cultures), catheter-tip colonisation (using CVC-tip cultures) and catheter-associated BSI.
In a recently published randomised controlled trial, use of alcohol plus octenidine to disinfect the insertion site and for CVC care led to a significant reduction in skin and catheter-tip colonisation and a reduction in CA-BSIs [12] . We conducted the risk factor analysis in the subgroup of haematology patients recruited in this trial [12] .
Methods

Setting and participants
Patient recruitment was carried out from 2002 through 2005 at the haematology units of University Medical Center Freiburg (Freiburg, Germany; referred to as FR) and University Hospital Basel (Basel, Switzerland; referred to as BS). Both institutions are tertiary care facilities with 1,500 and 1,000 beds, respectively.
Adult inpatients scheduled to receive a non-tunnelled CVC for an expected period of five or more days were asked for their informed consent. Exclusion criteria were known sensitisation against the proposed antiseptics, administration of antimicrobial drugs for therapy (not prophylaxis) less than one week prior to catheterisation, pre-existing BSI (i.e. fever and/or other signs of infection, positive blood culture), and patients with burns. In addition, patients participating in a clinical trial on other antiseptics within a period of four weeks were excluded. Patients who received a new catheter after the follow-up period, i.e. at earliest 30 days after removal of the first catheter, were permitted to enrol again.
Before catheterisation, the entry site was disinfected over an area of >200 cm 2 for at least 1 min. Applied skin antiseptics were either alcohol-based or alcohol-based plus 0.1% octenidine (randomly assigned, stratified by centre). After insertion, which was performed under sterile barrier precautions according to a standard protocol, the catheter was dressed with sterile gauze or a semi-permeable transparent dressing. Skin antiseptics were also used for care of the entry site during the change of dressings. Change of dressings and skin antisepsis were performed according to a standard protocol in both centres.
Patient and catheter characteristics were recorded for each procedure in a case report form. The patients' participation in the study ended with removal of the CVC or stop of treatment with the assigned study medication.
Recorded variables for risk factor analysis were: study centre (FR, BS), age (in years), gender, bone marrow or peripheral stem cell transplantation (yes, no), type of transplantation (autologous, related-allogeneic, unrelatedallogeneic), hospital stay prior to CVC placement (in days), insertion site (jugular, subclavian), CVC type (antimicrobial [AM] coated with chlorhexidine and silver sulfadiazine, uncoated), number of CVC lumen (1-2, 3), type of primary wound dressing (gauze, semi-permeable transparent dressing), duration of catheterisation (≤21 days, >21 days), administration of AM drugs (yes, no), cytostatics via CVC (yes, no), parenteral nutrition via CVC (yes, no), blood products via CVC (yes, no), neutropenia defined as leucocyte count <1,000/mm 3 (yes, no). The influence of the factors insertion site, number of CVC lumen, primary wound dressing, and cytostatics via CVC were not analysed due to their asymmetric distribution or their imbalanced distribution in the study centres FR and BS. Further details on study setting and participants have been previously described by Dettenkofer et al. [12] .
Endpoints and microbiology
The following endpoints were investigated: (1) baseline skin colonisation, (2) subsequent skin colonisation, (3) positivity of the catheter-tip (≥15 colony forming units [CFU] ) and (4) occurrence of CA-BSI 1, 2 Quantitative skin cultures were obtained before insertion and at regular intervals (3±1 days) from a 6×4-cm area of skin around the catheter insertion site using a sterile template [13] . A sterile, moistened cotton applicator was swabbed around the insertion site and across the surrounding 24 cm 2 area. The applicator was then placed in a tube containing 1.0 mL of 0.01 M phosphate-buffered saline and taken to the laboratory. After vortex mixing and diluting (1:10), aliquots of 0.1 ml of the suspension and of the dilution and 0.01 ml of the dilution only were plated onto blood agar plates. Colonies were counted after incubation at 35°C for 48 h and the mean value (CFU/24 cm 2 ) was calculated.
3.
After removal, CVC-tip was cultured applying the rollplate technique. Colonisation was defined as ≥15 CFU [14] . Results were standardised for a 5-cm segment of the catheter by dividing CFU count by actual length of CVC-tip in centimetres, multiplied by five. 4. CVC-associated (primary), laboratory-confirmed bloodstream infection (CA-BSI) 4a CA-BSI was defined according to CDC criteria [15] as: isolation of a recognised pathogen from one blood culture that was unrelated to an infection at another site; and/or: fever, shivering, or hypotension; and one of the following: isolation of a common skin contaminant from two separate blood cultures that was unrelated to an infection at another site, isolation of a common skin contaminant from one blood culture for patients with an intravascular device for whom a physician initiated appropriate antimicrobial therapy, or a blood test result positive for an antigen of a pathogen that was unrelated to an infection at another site. CA-BSI was observed from CVC placement up to two days after catheter removal or, in case of patient transfer to another ward or hospital before catheter removal, up to two days after transfer (leading to stop of treatment with the study medication). This observation period was defined as days at risk. 4b Catheter-related (CR)-BSI; in addition to CA-BSI, if bacterial species matched between blood and catheter-tip culture.
Statistical analysis
The effect of the risk factors on the endpoints (1) baseline colonisation, (2) subsequent colonisation, (3) positivity of the catheter-tip, (4) occurrence of CVC-associated BSI was analysed.
For the analysis of endpoint (1), the logarithm of the CFU value before CVC insertion was calculated, and for the analysis of endpoint (2) , the mean of the logarithm of the CFU values measured within the first 10 days was calculated. The effect of the risk factors on endpoints (1) and (2) was analysed with a linear regression model. Statistical tests were performed without adjustment for multiple testing. To quantify the effect, the relative difference between groups was calculated as the difference of the adjusted means of the logarithm of the CFU values, transformed with the exponential function, with 95% confidence interval (CI). The factors study centre, age, gender, transplantation, and hospital stay prior to CVC placement were analysed with regard to endpoints (1) and (2) . All factors were examined in multivariate analyses, including all factors simultaneously in one model. Additionally, the effect of endpoint (1) on endpoint (2) was analysed.
The effect of the risk factors on endpoints (3) and (4) was analysed with a logistic regression model. The effects were tested using Wald tests without adjustment for multiple testing. To quantify the effect, the odds ratio (OR) was calculated with 95% CI. The factors study centre, age, gender, transplantation, type of transplantation, hospital stay prior to CVC placement, CVC type, duration of catheterisation, administration of AM drugs, parenteral nutrition via CVC, blood products via CVC, and neutropenia, were analysed with regard to endpoints (3) and (4). All factors were examined in univariate analyses, including one factor at a time. Additionally, the effects of endpoints (1) and (2) on endpoints (3) and (4) were analysed, and all analyses of endpoint (3) included endpoint (1) for adjustment. Multivariate analyses, including more factors simultaneously in one model, were not performed because of the small number of patients experiencing endpoints (3) and (4) .
All analyses were performed in the whole study group and separately in study centres FR and BS, because study centres were heterogeneous with respect to some aspects of the catheterization. A separate analysis of the effects of the risk factors on endpoints (3) and (4) in study centre BS could not be performed, because only few patients experienced endpoints (3) and (4) in centre BS. The effect of CVC type was analysed only in study centre FR.
All analyses were based on complete cases, i.e. patients with complete endpoint and risk factor assessment.
In the primary analyses, no adjustment for randomised treatment was performed. Sensitivity analyses including the randomised treatment for adjustment were also conducted for endpoints (2), (3) and (4). This adjustment did not change the results substantially.
Results
Two hundred nineteen haematology patients were enrolled resulting in 5,501 catheter days and 4,275 days at risk (Table 1) .
Jugular insertion site was chosen in nearly all FR patients (96%) whereas BS mainly chose the subclavian site (88%). FR used uncoated CVCs in 60% of cases, BS exclusively chlorhexidine silver-sulfadiazine-coated CVCs.
Baseline colonisation
Age was an independent risk factor for baseline colonisation with a 1.04-fold increase per additional year (95% CI [1.02, 1.07], p=0.002). Patients in study centre BS had a 0.09-fold decreased baseline colonisation (95% CI [0.04, 0.20], p<0.0001). All results are shown in Table 2 .
Predominant microorganisms in baseline skin swabs were coagulase negative staphylococci (CNS: N=193 in 213 patients, 91%) followed by other cocci (pooling all cocci except Staphylococcus aureus, CNS, streptococci, and enterococci, N = 57, 27%), aerobic spore-forming bacteria (N= 30, 14%), Corynebacterium spp. (N =18, 8%), streptococci (N=17, 8%), S. aureus (N=11, 5%), and other nonfermenting bacteria (N=10, 5%).
Subsequent skin colonisation
Independent risk factor for subsequent skin colonisation was baseline colonisation showing a 1.43-fold increase in Table 3 . Microorganisms in subsequent skin swabs were largely comparable to those at baseline. However, moulds were not seen in baseline swabs. Predominant microorganisms were CNS (N=163 in 200 patients, 82%) as predominant bacteria, followed by other cocci (N=72, 36%), aerobic spore-forming bacteria (N=30, 15%), Corynebacterium spp. (N=23, 12%) , streptococci (N=20, 10%), moulds (N=19, 10%), and other nonfermenting bacteria (N=15, 8%).
CVC-tip colonisation
Colonised CVC-tips (≥15 CFU) were found in 24 cases (13.7%). Forty-four CVC-tips were not available (e.g. contamination of tip during removal, hospital discharge with catheter in place, tip not sent to laboratory), see Table 1 .
Subsequent skin colonisation was a risk factor for CVC-tip colonisation with an OR of 1.20 for CVC-tip colonisation per mean logCFU within 10 days after CVC insertion (95% CI [1.04, 1.40], p=0.015). The median logCFU for skin colonisation was 4.9 in patients with a colonised CVC tip, as compared to 2.0 in patients without a colonised CVC tip.
Risk for CVC-tip colonisation in study centre BS as compared to study centre FR was estimated with an OR of 0.30 (95% CI [0.08, 1.11], p=0.07). Patients who underwent transplantation had a slightly increased risk (17.8%) vs. patients who did not undergo transplantation (7.4%). In study centre FR, chlorhexidine and silver-sulfadiazinecoated catheters showed a slightly (non significant) reduced colonisation rate. All results are shown in Table 4 .
Most frequently isolated microorganisms were CNS (N= 22 in 175 patients, 13%), followed by enterococci, Corynebacterium spp., S. aureus, and Enterobacter spp. (N=1, 1% each).
Laboratory-confirmed CA-BSI Twenty-four cases of CA-BSI occurred. The incidence density was 5.6 per 1,000 days at risk. In nine patients, no information on the occurrence of BSI was available.
Subsequent skin colonisation was a risk factor for CA-BSI with an OR of 1.15 for CVC-tip colonisation per mean logCFU within 10 days after CVC insertion (95% CI [1.02, 1.29], p= 0.028). The median logCFU was 3.4 in patients with CA-BSI, as compared to 2.3 in patients without CA-BSI.
Risk for CA-BSI in study centre BS as compared to study centre FR was estimated with an OR of 0. 21 Table 5 . Most frequently isolated microorganisms were CNS (N= 9 in 210 patients, 4%), followed by Escherichia coli (N=7, 3%), S. aureus, streptococci, enterococci, Enterobacter spp. (N=2, 1% each).
Catheter-tip was not colonised in 18 of 24 patients with CA-BSI and in 18 patients with colonised CVC-tip, no BSI occurred. CR-BSI occurred in four cases (3× CNS; 1× S. aureus). In one patient with CA-BSI caused by CNS, the catheter-tip was not available for analysis; in one patient with positive CVC-tip (CNS) no data on BSI were available. One patient had a positive CVC-tip (CNS) and positive blood culture results for E. coli.
Discussion
We determined CA-BSI and CVC-tip colonisation rates and examined risk factors for skin and CVC-tip colonisation and CA-BSI in a haematology patient group of two university medical centres. Age and study centre FR was associated with higher skin colonisation at baseline before CVC placement. Male gender, baseline colonisation and study centre FR was associated with higher subsequent skin colonisation within 10 days after CVC placement. The CVC-tip colonisation rate was slightly higher in study centre FR than in study centre BS, and increased skin colonisation within 10 days after CVC placement was associated with a higher CVC-tip colonisation rate. Subsequent skin colonisation, autologous transplantation and study centre FR was associated with a higher CA-BSI rate.
Incidence density of CA-BSI was 5.6 per 1,000 days at risk. CVC-tip colonisation occurred in 14% (24 out of 175) of patients.
The major strength of this study is the standardised treatment with two alcohol-based skin antiseptics, rando- mised to alcohol plus octenidine vs. alcohol alone, since a valid analysis of risk factors is only possible if study treatment is standardised [16] . Further strengths of the study are high data quality with prospective collection at two study centres, prospective planning and conduct of statistical analyses by an independent clinical trials centre. However, there are some limitations to mention. Hub colonisation was not evaluated; therefore, no conclusions can be made concerning this component in pathogenesis of CA-BSI. Study centres were free of choice for variables like insertion site (which varied considerably), dressing, CVC type. Thus, some variables had to be excluded from statistical analysis due to asymmetric distribution. Standardised protocols concerning CVC placement and insertion site care were established but compliance was only controlled on planned dressing changes with skin swabs conducted by study assistants. CVC insertion itself and unscheduled dressing changes were not observed continuously. Despite accurate standards for skin swabs and laboratory work, involvement of different study assistants in two centres could possibly create variations in results. The results on CVC-tip colonisation and occurrence of CA-BSI are based on small numbers of the corresponding events, and must be interpreted with some caution.
Skin colonisation
There are few trials published evaluating risk factors for skin colonisation at the CVC insertion site. Duration of catheterisation, male gender, age, jugular insertion site, non-compliance with maximal sterile barrier precautions, transparent dressing and hub colonisation were found to be risk factors for skin colonisation [17, 18] . In our trial, age was a risk factor for baseline colonisation but did not show a further effect on subsequent colonisation being adjusted for baseline colonisation. Moro et al. showed an effect of age only if a transparent dressing was used [17] . Once a CVC is in place, effects of skin antiseptics and dressings are most likely to outreach age-related changes in skin characteristics (like less fat content, elasticity and moisture) [19] and their effects on skin microflora.
Male gender was an independent risk factor for baseline and subsequent colonisation. Beard growth reduces adherence of wound dressing materials in male patients and increases the risk of contamination as does shaving. Both Moro et al. [17] and Carrer et al. [18] found male gender to be a risk factor for skin colonisation, but Moro et al. [17] could show this only for jugular access. In the separate analysis of study centres, we found the effect of male gender only in centre FR and not in centre BS. If the distribution of insertion sites is taken into account, this strongly supports the finding of Moro et al. [17] , as jugular insertion site was chosen in 99% of male patients in centre FR and in only 17% in centre BS. In addition, male gender was associated with higher risk for CA-BSI (which was more pronounced in centre FR). Current guidelines recommend weighing up infectious vs. non-infectious complications for subclavian vs. jugular access [20] . Our findings support giving preference to subclavian insertion site especially in male patients. Baseline colonisation itself was an independent risk factor for subsequent colonisation. This finding highlights the importance of adequate initial skin disinfection. In highly colonised patients, reduction of bacterial density on the insertion site could possibly be less effective than in initially less colonised patients. This could facilitate faster re-growth in these patients.
CVC-tip colonisation and CA-BSI As CR-BSI is a relatively rare event, CVC-tip colonisation is often used as surrogate parameter showing good correlation with CR-BSI [21] . In our trial, 18 patients with CVC-tip colonisation did not develop a CA-BSI. Eighteen of 24 patients with CA-BSI had no CVC-tip colonisation suggesting limited sensitivity of CVC-tip culture or additional mechanisms in BSI development in our patient group.
The CVC-tip colonisation rate of 14% in our trial is within the range (2.3-37.8%) of previously reported rates [22] [23] [24] . However, these data were not derived from haematology patients.
In the subgroup of transplanted patients, those with autologous Tx had an extensively higher BSI risk. This is not concordant with the literature. A recent analysis of 1,699 patients found no significant differences in BSI rates between different Tx types [25] . In our trial, a much smaller patient group was investigated. Other factors might have influenced this result especially as no multivariate analysis could be performed.
In our trial, subsequent skin colonisation was associated with CVC-tip colonisation which was also shown in a recent trial [22] and fits in with colonisation most likely starting extraluminal at the insertion site in short-term CVC [11] . Subsequent skin colonisation was also associated with a higher risk for CA-BSI. Initial skin antisepsis and insertion site care should intend maximal suppression of microbial growth and re-growth. Antiseptics containing remanent agents (e.g. octenidine dihydrochloride, chlorhexidine) should therefore be preferred due to their ability of prolonged reduction of microbial growth [12] . Consistently, current US and UK guidelines recommend chlorhexidine/alcohol as first-line antiseptic [20, 26] .
Application of sponges containing remanent antiseptic agents on CVC insertion site is a promising option for infection prevention as recently published data showed [27, 28] . As a high-risk group, haematology patients could benefit from such interventions. This is also supported by our findings.
Results of routine skin cultures as an option for identifying patients at high risk for BSI, as Bouza et al. showed in cardiac surgery ICU patients [29] could be used for targeted additional preventive measures.
Results regarding chlorhexidine and silver-sulfadiazinecoated CVC were inconsistent showing a trend to lower CVCtip colonisation rates but a trend to higher CA-BSI-rates in centre FR.
Incidence density of CA-BSI (5.6/1,000 days at risk) was lower compared to surveillance data derived from neutropenic patients undergoing HCT (14/1,000 neutropenic days) [10] . This seems plausible, as most nosocomial infections in this patient group occur during neutropenia [30] and we investigated both the neutropenic and nonneutropenic phase, showing neutropenia as a risk factor for CA-BSI.
Influence of study centre Noticeable differences in outcome variables were found between study centres. Study centre FR was associated with baseline and subsequent skin colonisation, CVC-tip colonisation, and CA-BSI. Choice of CVC insertion site showed a conspicuous difference between centres (subclavian: 88% BS vs. 4% FR). Disregarding this fact, patients in centre FR had higher colonisation rates on both insertion sites compared to BS (median logCFU jugular/subclavian: FR 2.9/3.2; BS 1.6/0.0). This leads to conclude that other factors must also contribute to this effect. In spite of established standards, involvement of different study assistants for skin swabs could possibly affect results, as some variables (e.g. pressure exerted while swabbing) are hard to standardise.
Preference of subclavian insertion site in BS could have had an influence on CA-BSI rates. In several previous trials the subclavian site was shown to have lower infection and CVC-tip colonisation rates and is recommended in recent guidelines for infection prevention [26, [31] [32] [33] [34] [35] . Differences in nurse staffing which were not evaluated could be a further possible influencing factor. Care of CVC patients by "float" nurses was previously shown to be a risk factor for BSI [36] .
